Vor Biopharma (VOR)
NASDAQ:VOR
Want to see VOR full AI Analyst Report?
Top Page
Vor Biopharma
(NASDAQ:VOR)
Select Model
Select Model
Rating:47Neutral
Price Target:
$14.00
▼(-15.61% Downside)
Action:ReiteratedDate:04/01/26
The score is held down primarily by weak financial performance (no revenue, heavier losses, persistent cash burn, and negative equity). Technicals are only modestly constructive (price above shorter-term averages but below the 200-day with slightly negative MACD), while valuation remains unattractive due to ongoing losses and no dividend. Corporate events provide some offset via fresh financing and continued clinical program progress.
Positive Factors
Proprietary HSC engineering platform
Vor's engineered allogeneic hematopoietic stem cell approach is a structural competitive asset: removing targets on healthy cells to enable paired targeted agents can address core safety constraints of cell therapies. If clinically validated, the platform enables multiple indications and durable differentiation versus single-drug competitors.
Negative Factors
No revenue; widening net losses
The absence of any revenue and a dramatic increase in net losses indicate the company remains pre-revenue and highly reliant on capital markets. Such sustained losses reduce optionality, raise dilution risk, and mean profitability is contingent on successful clinical outcomes and commercialization—outsized binary execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary HSC engineering platform
Vor's engineered allogeneic hematopoietic stem cell approach is a structural competitive asset: removing targets on healthy cells to enable paired targeted agents can address core safety constraints of cell therapies. If clinically validated, the platform enables multiple indications and durable differentiation versus single-drug competitors.
Read all positive factors
Vor Biopharma (VOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$685.33M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)4.59
Revenue GrowthN/A
EPS Growth-880.05%
CountryUS
Employees159
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)82.04
Shares Outstanding48,847,504
10 Day Avg. Volume1,359,391
30 Day Avg. Volume1,218,320
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap-0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit350.62
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$36.00Price Target Upside117.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.57
Revenue Forecast (FY)N/A
Vor Biopharma Business Overview & Revenue Model
Company Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other...
How the Company Makes Money
null...
Vor Biopharma Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -3.49M | -8.96M | 0.00 |
| EBITDA | -368.75M | -117.66M | -114.37M | -83.13M | -67.58M |
| Net Income | -695.98M | -116.91M | -117.86M | -92.09M | -68.90M |
Balance Sheet | |||||
| Total Assets | 464.13M | 142.89M | 209.83M | 299.37M | 242.59M |
| Cash, Cash Equivalents and Short-Term Investments | 455.21M | 91.93M | 137.18M | 230.25M | 207.47M |
| Total Debt | 3.00M | 31.83M | 35.66M | 38.91M | 18.01M |
| Total Liabilities | 628.44M | 46.23M | 59.10M | 48.76M | 26.33M |
| Stockholders Equity | -164.31M | 96.66M | 150.72M | 250.61M | 216.26M |
Cash Flow | |||||
| Free Cash Flow | -143.65M | -99.89M | -101.36M | -93.61M | -73.04M |
| Operating Cash Flow | -142.71M | -99.66M | -100.29M | -85.14M | -69.14M |
| Investing Cash Flow | -48.80M | 96.86M | 71.01M | -94.09M | -91.65M |
| Financing Cash Flow | 503.81M | 53.39M | 2.94M | 117.14M | 232.91M |
Vor Biopharma Technical Analysis
Positive
16.59
Price Trends
14.61
Positive
13.54
Positive
23.96
Negative
Market Momentum
0.43
Positive
57.11
Neutral
39.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Positive. The current price of 16.59 is above the 20-day moving average (MA) of 15.24, above the 50-day MA of 14.61, and below the 200-day MA of 23.96, indicating a neutral trend. The MACD of 0.43 indicates Positive momentum. The RSI at 57.11 is Neutral, neither overbought nor oversold. The STOCH value of 39.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VOR.
Vor Biopharma Risk Analysis
Vor Biopharma disclosed 81 risk factors in its most recent earnings report. Vor Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vor Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $147.23M | 6.18 | 17.46% | ― | ― | ― | |
57 Neutral | $432.62M | -1.84 | -46.34% | ― | ― | 2.37% | |
57 Neutral | $508.45M | -2.58 | -81.41% | ― | ― | -5.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $255.34M | -3.23 | -90.51% | ― | 18.61% | 42.63% | |
47 Neutral | $685.33M | -0.19 | 72.70% | ― | ― | -880.05% | |
47 Neutral | $186.15M | -1.42 | -91.52% | ― | 11.66% | 3.83% |
* Healthcare Sector Average
VOR
Vor Biopharma
14.03
0.45
3.31%
CDXS
Codexis
2.81
0.51
22.17%
BDTX
Black Diamond Therapeutics
2.57
0.87
51.18%
AVIR
Atea Pharmaceuticals
5.43
2.48
84.07%
CRBU
Caribou Biosciences
1.92
1.07
125.88%
KYTX
Kyverna Therapeutics, Inc.
8.40
6.09
263.64%
Vor Biopharma Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Vor Biopharma Announces $75 Million Private Placement Financing
Positive
Mar 27, 2026
On March 26, 2026, Vor Biopharma Inc. entered into a securities purchase agreement with healthcare investment firm TCGX for a $75 million private placement of 5,338,078 common shares at $14.05 per share, with closing expected around March 30, 2026...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.